# US 2008/0313747 A1 · Targeted Transgenesis of Short Hairpin Rna Expression Cassettes Using Recombinase Mediated Cassette Exchange

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0313747 A1
- Document ID: US20080313747A1
- Status: Published application
- Kind: A1
- Application number: 11/571,194
- Filed: 2005-07-07
- Published: 2008-12-18
- Earliest claimed: 2004-07-07
- Inventors: Heidrun Kern; Jost Seibler; Frieder Schwenk
- Web page: https://patentgrep.com/patent/US20080313747A1

## CPC

- C12N 15/907: {in mammalian cells}
- A01K 2217/058: due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The invention provides a method for targeted transgenesis of short hairpin RNA expression cassettes using recombinase mediated cassette exchange. Suitable nucleotide acid sequences and vectors for the targeted transgenesis and recombinase mediated transgenesis are provided.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

Method for generating transgenic eukaryotic cells having an ubiquitous locus modified by an expression cassette comprising a short hairpin RNA construct operatively linked to a promoter or an inactive precursor thereof, which method comprises introducing the expression cassette into the ubiquitous locus of eukaryotic cells by recombinase mediated cassette exchange (RMCE).

### Claim 22 (depends on 21)

The method of claim 21, which comprises
(a) introducing a functional DNA sequence into the Rosa26 locus of starting eukaryotic cells by homologous recombination with a targeting vector comprising flanking DNA sequences homologous to the ubiquitous locus and an acceptor DNA, which integrates into the genome of the starting cell, the acceptor DNA comprising two mutually incompatible first recombinase recognition sites (RRSs), and
(b) effecting RMCE of the recombination product of step (a) having RMCE target sites with an exchange vector comprising a donor DNA, which comprises the expression cassette flanked by the same two mutually incompatible first RRSs contained in the acceptor DNA, by utilizing a recombinase which catalyzes recombination between the RRSs of the acceptor and donor DNA.

### Claim 23 (depends on 21)

The method of claim 21, wherein the eukaryotic cells are derived from multi-cell organisms selected from the groups of organisms consisting of vertebrates, invertebrates and plants.

### Claim 24 (depends on 23)

The method of claim 23, where the eukaryotic cells are vertebrate cells.

### Claim 25 (depends on 24)

The method of claim 24, where the vertebrate cells are derived from mammals.

### Claim 26 (depends on 25)

The method of claim 25, wherein the mammals are non-human mammals.

### Claim 27 (depends on 26)

The method of claim 26, wherein the non-human mammals are rodents.

### Claim 28 (depends on 27)

The method of claim 27, wherein the rodents are selected from the group consisting of mouse and rat.

### Claim 29 (depends on 24)

The method of claim 24, wherein the vertebrates cells are derived from fish.

### Claim 30 (depends on 29)

The method of claim 29, wherein the fish is zebrafish.

### Claim 31 (depends on 21)

The method of claim 21, wherein the eukaryotic cells are selected from the group consisting of primary cells and immortalized cells.

### Claim 32 (depends on 31)

The method of claim 31, wherein the cells are mammalian embryonic stem (ES cells).

### Claim 33 (depends on 21)

The method of claim 21, wherein the ubiquitous locus is selected from the group consisting of Rosa26, Collagen, β-Actin, HPRT, U6, H1, tRNA, and 7SL RNA.

### Claim 34 (depends on 33)

The method of claim 33, wherein the ubiquitous locus is a Rosa26 locus.

### Claim 35 (depends on 21)

The method of claim 21, which is performed in vitro.

### Claim 36 (depends on 21)

The method of claim 21, wherein the promoter is a heterologous promoter.

### Claim 37 (depends on 36)

The method of claim 36, wherein the promoter is selected from the group consisting of ubiquitous and tissue specific promoters, either constitutive or inducible.

### Claim 38 (depends on 22)

The method of claim 22, wherein the targeting vector, the exchange vector and the expression cassette, independently from each other, further comprises one or more additional functional sequences selected from the group consisting of marker genes, second recombinase recognition sites differing from the first recombinase recognition sites, poly A signal and introns.

### Claim 39 (depends on 22)

The method of claim 22, wherein the targeting vector and the exchange vector, independently from each other, further comprises one or more additional functional sequences selected from the group consisting of tags for protein detection, enhancers and selection markers.

### Claim 40 (depends on 22)

The method of claim 22, wherein the targeting vector further comprises a gene coding for the recombinase which catalyses recombination between acceptor and donor DNA.

### Claim 41 (depends on 22)

The method of claim 22, wherein in step (a) the DNA sequences homologous to the ubiquitous locus are 0.2 to 20 kB long.

### Claim 42 (depends on 41)

The method of claim 41, where the DNA sequences are 1 to 10 kB long.

### Claim 43 (depends on 22)

The method of claim 22, wherein the mutually incompatible RRS are selected from the group consisting of pairs of mutually incompatible loxP, FRT, and Att sites or variants thereof.

### Claim 44 (depends on 43)

The method of claim 43, wherein the mutually incompatible RRS are selected from the group consisting of the following group of mutually incompatible RRS pairs: F3/FRT, F5/FRT, F5/F3, lox/lox511, lox/lox2722, lox66/lox71 and AttB/AttP.

### Claim 45 (depends on 22)

The method of claim 22, wherein the recombinase, which may be added to the cell or may be expressed by the cell, is selected from recombinases suitable for cassette exchange of the first RSSs present in the acceptor/donor DNA.

### Claim 46 (depends on 45)

The method of claim 45, wherein the recombinase is selected from the group consisting of Cre, Flp, Φ31 and mutants thereof.

### Claim 47 (depends on 21)

The method of claim 21, wherein the short hairpin RNA construct comprises one or more additional functional sequences selected from the group consisting of stop and polyadenylation sequences.

### Claim 48 (depends on 37)

The method according to claim 37, wherein the ubiquitous promoter is selected from the group consisting of polymerase I, II and III dependent promoters.

### Claim 49 (depends on 48)

The method of claim 48, wherein the ubiquitous promoter is selected from the group consisting of polymerase II and III dependent promoters.

### Claim 50 (depends on 49)

The method of claim 49, wherein the promoter is selected from the group consisting of a CMV promoter, a CAGGS promoter, a Mx promoter, a PGK promoter, a snRNA promoter, a RNAse P RNA promoter, a tRNA promoter, a 7SL RNA promoter, and a 5 S rRNA promoter.

### Claim 51 (depends on 37)

The method of claim 37, wherein the tissue specific promoter is selected from the group consisting of FABP, Lck, CamKII, CD19, Keratin, Albumin, a P2, Insulin, MCK, MyHC, WAP and Col2A promoters.

### Claim 52 (depends on 37)

The method of claim 37, wherein the ubiquitous promoter is selected from the group consisting of constitutive and inducible promoters.

### Claim 53 (depends on 52)

The method of claim 52, wherein the ubiquitous promoter is a promoter containing an operator sequence selected from the group consisting of tet, Gal4, lac, and RRSs for recombinase mediated control.

### Claim 54 (depends on 37)

The method of claim 37, wherein the promoter of the expression cassette is a Pol III dependent promoter.

### Claim 55 (depends on 54)

The method of claim 54, wherein the expression cassette is a constitutive H1 or U6, driven shRNA construct suitable to be integrated into a ubiquitously active Pol II dependent locus.

### Claim 56 (depends on 55)

The method of claim 55, where the expression cassette is an inducible U6 or H1 driven shRNA construct suitable to be integrated into a ubiquitously active Pol II dependent locus.

### Claim 57 (depends on 37)

The method of claim 37, wherein the promoter of the expression cassette is a Pol II dependent promoter.

### Claim 58 (depends on 57)

The method of claim 57, wherein the expression cassette is an inducible CMV driven shRNA construct suitable to be integrated into a ubiquitously active Pol II dependent locus.

### Claim 59 (depends on 21)

The method of claim 21, wherein the short hairpin RNA construct or the inactive precursor thereof comprises at least one segment corresponding to a short hairpin RNA (ShRNA).

### Claim 60 (depends on 59)

The method of claim 59, wherein the short hairpin RNA construct comprises at least one shRNA segment having a DNA sequence selected from the group consisting of A-B-C and C-B-A, wherein
A is a 15 to 35 bp DNA sequence with at least 95% complementarily to the gene to be knocked own;
B is a spacer DNA sequence having 5 to 9 bp forming the lop of the expressed RNA hair pin molecule, and
C is a 15 to 35 bp DNA sequence with at least 85% complementarily to the sequence A.

### Claim 61 (depends on 21)

The method of claim 21, wherein the short hairpin RNA construct or the inactive precursor thereof comprises at least two complementary short interfering RNA (siRNA) strands.

### Claim 62 (depends on 61)

The method of claim 61, wherein the short hair RNA construct comprises at least two siRNA segments selected from the group consisting of A and C, and C and A, each of said at least two siRNA segments being under the control of a separate precursor, wherein
A is a 15 to 35 bp DNA sequence with at least 95% complementarily to the gene to be knocked down;
B is a spacer DNA sequence having a 5 to 9 bp forming the loop of the expressed RNA hair pin molecule, and
C is a 15 to 35 bp DNA sequence with at least 85% complementarily to the sequence A.

### Claim 63 (depends on 23)

The method of claim 23, wherein the transgenic eukaryotic cells are derived from mouse and the ubiquitous locus is a Rosa 26 locus.

### Claim 64 (depends on 63)

The method of claim 63, wherein the DNA sequences homologous to the Rosa26 locus are derived from the 5′ and 3′ flanking arm of the mouse Rosa26 locus.

### Claim 65 (depends on 64)

The method of claim 64, wherein said homologous DNA sequences have the sequences shown in SEQ ID NO:4 and 5.

### Claim 66 (depends on 44)

The method of claim 44, wherein the RRSs of the targeting and exchange vectors are F3/Frt and the targeting vector encodes the recombinase Flp or a mutant thereof.

### Claim 67 (depends on 66)

The method of claim 66, wherein the recombinase is Flpe.

### Claim 68 (depends on 39)

The method of claim 39, where the targeting vector comprises a negative selection marker.

### Claim 69 (depends on 39)

The method of claim 39, where the exchange vector comprises a promoter-less positive selection marker.

### Claim 70 (depends on 36)

The method of claim 36, where the promoter of the expression cassette is a H1 or H6 promoter.

### Claim 71 (depends on 21)

The method of claim 21, where the targeting vector has the sequence shown in SEQ ID NO:11 and the exchange vector has the sequence shown in SEQ ID NO:12 or a variant thereof with modification in the short hairpin RNA construct.

### Claim 72 (depends on 22)

The method according to claim 22, which further comprises one or more of the steps
(c) isolating the eukaryotic cells, the ES cells having the desired functional exchange cassette or the inactive precursor integrated into the ubiquitous locus; and
(d) optionally modifying the integrated precursor of the expression cassette to activate the precursor and isolating ES cells having the desired modified functional exchange cassette.

### Claim 73 (depends on 22)

An exchange vector comprising the expression cassette and a donor DNA, as defined in claim 22.

### Claim 74 (depends on 21)

A eukaryotic cell having a modified ubiquitous locus obtainable by the method of claim 21.

### Claim 75 (depends on 21)

A method for preparing transgenenic multi-cell organism having a modified ubiquitous locus which comprises transfecting eukaryotic cells according to the method defined in claim 21.

### Claim 76 (depends on 73)

A method for preparing transgenenic multi-cell organism having a modified unbiquitous locus which comprises injecting an exchange vector of claim 73 into an early stage embryo of a non-human mammal having corresponding RMCE target sites.

### Claim 77 (depends on 75)

The method of claim 75, wherein the transgenenic multi-cell organism is a non-human mammal, said ubiquitous locus is a Rosa26 locus, and said method comprises modifying an ES cell.

### Claim 78 (depends on 75)

The method of claim 75, which further comprises one or more of the steps (e) injecting ES cells obtained in steps (c) or (d) into blastocysts; and (f) generating transgenic non-human multi-cell organisms or non-human mammals carrying one or more functional genes of interest at the Rosa26 locus.

### Claim 79 (depends on 75)

A transgenic multi-cell organism or a tissue culture derived therefrom or a transgenic non-human mammal or a tissue culture derived therefrom, which are obtainable by the method of claim 75, respectively, and having an operatively functional gene expression cassette integrated into at least one of its loci.

### Claim 80 (depends on 22)

A method for constitutive and/or inducible gene knock down in a multi-cell organism, or in a tissue culture or cells of a cell culture derived from said multi-cell organism, which comprises stably integrating an expression vector as defined in claim 22 into the genome of the living organism, of the tissue culture or of the cells of the cell culture.

### Claim 81 (depends on 79)

The method of claim 79, wherein (i) the expression vector is integrated at the Rosa26 locus of the multi-cell organism, tissue culture or cell culture.

### Claim 82 (depends on 79)

The method of claim 79, wherein the method for constitutive and/or inducible gene knock down in a vertebrate comprises integrating the expression vector into ES cells of the vertebrate.

### Claim 83 (depends on 74)

Method of using the eukaryotic cell of claim 74 for gene function studies and drug development.

### Claim 84 (depends on 79)

Method of using the transgenic multi-cell organism, tissue culture or non-human mammal of claim 79 for gene function studies, drug development and disease model animals.
